Viking Therapeutics ( ($VKTX) ) has risen by 7.76%. Read on to learn why. Viking Therapeutics has seen a notable 7.76% ...

We came across a bullish thesis on Viking Therapeutics, Inc. on r/wallstreetbets subreddit by Dritzz-9966. In this article, ...

Viking Therapeutics shares fall in Wednesday's after-hours session after the company reported financial results for the ...

Viking Therapeutics has strong R&D, dual-track obesity drugs, and solid cash runway. Click here to read an analysis of VKTX ...

Analysts expect Viking Therapeutics to report an earnings per share (EPS) of $-0.44. The announcement from Viking ...

Every investor in Viking Therapeutics, Inc. (NASDAQ:VKTX) should be aware of the most powerful shareholder groups. We can see that institutions own the lion's share in the company with 70% ownership.

Eli Lilly is a leader in the weight loss drug market, generating blockbuster revenue. Viking Therapeutics recently launched a phase 3 trial for its weight loss candidate -- and could have a promising ...

Viking Therapeutics (NASDAQ: VKTX) has captured the attention of investors, with its stock price skyrocketing over 400% in one year. This remarkable performance stems from the company's promising ...

Viking Therapeutics' leading pipeline candidate, VK2735, is a potential dual GLP-1/GIP medicine. Both classes of drugs help control satiety but with different mechanisms.

Viking Therapeutics Annual Revenue Estimates (Seeking Alpha) I would like to point out that the consensus estimate has Viking going from $2.5M in 2025… to nearly $2.5B in 2030.